The association between comorbidities and disease activity in patients with rheumatoid arthritis: a multicenter, cross-sectional cohort study in Japan with the highest proportion of elderly individuals

Takanori Miura1,2*, Naohisa Miyakoshi3, Takeshi Kashiwagura2, Hiroyuki Tsuchie3, Yusuke Sugimura2 and Yoichi Shimada2

Abstract

Background: This study aimed to assess the association of disease activity with the presence of comorbidities in patients with rheumatoid arthritis, using the Akita Orthopedic Group on Rheumatoid Arthritis (AORA) registry, a multicenter, cross-sectional registry in Japan with the highest proportion of elderly people. We included 1838 patients (mean age: 66.4 years old) who visited our affiliated institutions between April 2018 and March 2019. The patients were divided into two groups based on the disease activity in 28 joints based on the erythrocyte sedimentation rate (DAS28-ESR) into the remission or low disease activity group (L group) and the moderate or high disease activity group (H group). Patient demographics and comorbidities in the two groups were compared.

Results: The most common comorbidity was hypertension (33.7%), followed by renal disease (25.2%), respiratory disease (12.2%), diabetes mellitus (8.1%), cardiovascular disease (8.0%), malignancies (5.7%), and cerebrovascular disease (4.7%). The H group was older (p<0.0001); had a higher prevalence of hypertension (p<0.0001), diabetes (p=0.0011), respiratory disease (p<0.0001), cerebrovascular disease (p<0.0001), and cardiovascular disease (p=0.0030); and was less likely to use anti-rheumatic drugs. The prevalence of comorbidities other than renal disease and malignant tumor was higher in the H group. Multivariate logistic regression analysis showed that female sex (p=0.0054), advanced Steinbrocker class (p<0.0001), high anti-citrullinated protein antibody levels (p=0.0211), high prednisolone dose (p<0.0001), and absence of biologics’ or JAK inhibitors’ use (p<0.0001) were risk factors for high disease activity, and shorter treatment period was a low-risk factor for high disease activity (p=0.0041). Among comorbidities, the presence of cerebrovascular disease (p=0.0334) was the only independent risk factor for high disease activity.

Conclusions: In our registry study with a high proportion of elderly RA patients, cerebrovascular disease was associated with high disease activity in patients with RA. Therefore, when treating elderly patients with RA, we need to pay careful attention to cerebrovascular disease, and treatment should be aimed at achieving adequate control of RA.

Keywords: Rheumatoid arthritis, Comorbidity, Treatment strategy, Cerebrovascular disease, Treat to target, Multicenter study

*Correspondence: tmlucky8@gmail.com
1 Department of Orthopedic Surgery, Kakunodate General Hospital, 3 Iwase Kakunodate, Senboku, Akita 014-0394, Japan
Full list of author information is available at the end of the article

© The Authors 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
**Background**

Rheumatoid arthritis (RA) is a chronic inflammatory disease that can lead to joint destruction and dysfunction due to synovitis and bone erosion. However, in the last decade, the introduction of disease-modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX), biologics (Bio), and Janus kinase inhibitors (JAK) has dramatically improved the long-term prognosis of patients with RA [1]. The concept of “treat-to-target” (T2T) in RA, which involves monitoring the disease activity in order to achieve remission or low disease activity, has been shown to be effective in improving pain and dysfunction [2, 3].

RA is more common in middle-aged people between the ages of 40 and 60 years [3], and treatment response to MTX and biologics has been reported to be similar among younger and older patients with RA [4]. However, the increased incidence of comorbidities, such as cardiovascular and respiratory diseases, with aging, often makes it difficult to introduce and continue these effective drugs [3, 4]. As a result, older patients with RA are more difficult to treat and have a higher disease activity [5–8]. Previous reports have also shown that patients with comorbidities have higher disease activity and poorer outcomes than those without comorbidities [5, 6, 9]. However, only few reports have examined the relationship between specific comorbidities and disease activity in RA [10]. Furthermore, there are no reports of studies that focus on elderly individuals with several comorbidities.

This study aimed to investigate which comorbidities affect disease activity in patients with RA using the Akita Orthopedic Group on Rheumatoid Arthritis (AORA) registry [11], a multicenter, cross-sectional RA cohort study in Japan with the highest proportion of elderly people.

**Methods**

**The AORA registry**

The AORA registry was established in 2010 as a multicenter cohort of Japanese patients with RA in Akita Prefecture, Japan. The AORA registry is maintained by the Department of Orthopedic Surgery at Akita University Graduate School of Medicine and covers 28 affiliated institutions. The data is collected once a year from the responsible physician at each institution. Japan is one of the world’s most rapidly aging countries, and the Akita Prefecture has the highest rate of aging, with 33.8% of the population aged ≥65 years [12]. Therefore, compared to other cohort registries [13, 14], the AORA registry is novel, owing to its high proportion of elderly patients.

**Study design**

We included 2175 patients with RA aged ≥18 years who visited our affiliated institutions between April 2018 and March 2019. Patients not assessed for comorbidities and those with insufficient clinical findings and laboratory data for assessment of disease activity were excluded; finally, 1838 patients (365 males and 1473 females) were included in this study. Patient information, including age, sex, medication, dosing period, disease stage and class per the Steinbrocker classification system [15], serum levels of anti-citrullinated protein antibody (ACPA), the disease activity score in 28 joints based on the erythrocyte sedimentation rate (DAS28-ESR), simplified disease activity index (SDAI), the health assessment questionnaire disability index (HAQ), and comorbidities, were collected. We investigated the use of the following drugs for RA: DMARDs, MTX, glucocorticoids (prednisolone, PSL), Bio, and JAK inhibitors (Bio/JAK). Regarding comorbidities, we evaluated the presence of hypertension; diabetes mellitus (DM); respiratory disease (chronic obstructive pulmonary disease (COPD), interstitial pneumonia (IP), asthma, and pulmonary infection); cerebrovascular disease (cerebral infarction, cerebral hemorrhage, and subarachnoid hemorrhage); cardiovascular disease (myocardial infarction, heart failure, and cardiomyopathy); renal disease; and malignancy. We defined renal disease as an estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73m² [16]. On the DAS28-ESR, remission was defined as <2.6, low disease activity as 2.6–3.2, moderate activity as 3.2–5.1, and high disease activity as >5.1 [17]. Therefore, we divided patients into two groups: the remission or low disease activity group (L group) and the moderate or high disease activity group (H group). We compared the measures between the two groups. Furthermore, factors that affected high disease activity were examined.

The study’s retrospective protocol was approved by the Institutional Review Board for Clinical Research at Kakunodate General Hospital (approval number, 00409), and informed consent was obtained from all patients.

**Statistical analysis**

Values are expressed as means and standard deviations (SD) for continuous variables and as percentages for categorical variables. Comparisons between groups were made using independent sample t tests in the case of continuous variables, and Pearson’s chi-square tests for categorical variables. To investigate the association between RA disease activity and comorbidities, a multivariate logistic regression analysis was performed. All statistical analyses were completed using R version 3.5.1 software (R Foundation for Statistical Computing, Vienna,
Austria), and the statistical significance was considered at a \( p \) value <0.05.

**Results**

The mean age was 66.4 ± 13.0 years (range, 18–99 years), and the mean disease duration period was 151.3 ± 129.0 months (range, 20–1040 months) (Table 1). Among patients who used biologics, etanercept was used in 175 patients (34.9%); tocilizumab in 68 patients (22.7%); abatacept in 68 patients (13.6%); adalimumab in 51 patients (10.2%); golimumab in 46 patients (9.2%); infliximab in 30 patients (6.0%); and certolizumab in 15 patients (3.0%). The JAK inhibitor tofacitinib was used in only two patients (0.4%). The most common comorbidity was hypertension, followed by renal disease, respiratory disease, DM, heart disease, malignant tumor, and cerebrovascular disease, in decreasing order of prevalence (Table 1).

| Variable                   | Value          |
|----------------------------|----------------|
| Total patients             | 1838           |
| Age (years)                | 66.4±13.0 (18–99) |
| Elderly (≥65)              | 1103 (60.0)    |
| Sex—male/female           | 365 (19.9)/1473 (80.1) |
| Disease duration (months)  | 151±129 (20–1040) |
| Steinbrocker stage I/II/III/IV | 517 (28.2)/407 (22.2)/442 (24.0)/472 (25.6) |
| Steinbrocker class I/II/III/IV | 856 (46.5)/729 (39.7)/207 (11.3)/46 (2.5) |
| ACPA (U/ml)                | 133±307 (0–7690) |
| DAS                        | ±2.9±1.2 (0.28–7.9) |
| SDAI                       | 7.3±6.8 (0.01–57.4) |
| HAQ                        | 0.5±1.2 (0–49) |
| DMARDs usage               | 1607 (87.4)    |
| MTX usage                  | 1117 (60.8)    |
| MTX dose (mg/week)         | 7.2±2.3 (1–14) |
| PSL usage                  | 711 (38.7)     |
| PSL dose (mg/day)          | 3.8±2.1 (0–25) |
| Biologics/JAK usage        | 501 (27.2)     |

**Table 1 Clinical information for all patients**

| Variable                  | Value                      |
|---------------------------|----------------------------|
| **Comorbidity**           |                            |
| Hypertension              | 619 (33.7)                 |
| Diabetes mellitus         | 149 (8.1)                  |
| Respiratory disease       | 224 (12.2)                 |
| Cerebrovascular disease   | 86 (4.7)                   |
| Cardiovascular disease    | 174 (8.0)                  |
| Renal disease             | 464 (25.2)                 |
| Malignant tumor           | 105 (5.7)                  |

Values are expressed as the number of patients (%) or the mean ± SD (range)

ACPA anticyclic citrullinated peptide antibody, DAS Disease Activity Score-28 joint count, HAQ Health Assessment Questionnaire, DMARDs disease-modifying anti-inflammatory drugs, MTX methotrexate, PSL prednisolone, JAK Janus kinase inhibitors, SD standard deviation

On comparing the two groups, the H group was older \( p(<0.0001) \); had a higher proportion of women \( p=0.0017 \); and had a longer disease duration \( p=0.0055 \), more advanced stage \( p(<0.0001) \) and Steinbrocker class \( p(<0.0001) \), and higher ACPA levels \( p=0.0034 \) than the L group. The usage rate of DMARDs \( p=0.0017 \), MTX \( p=0.0387 \), and Bio/JAK \( p(<0.0001) \) was lower in the H group; however, the usage rate and dose of PSL were higher in the H group \( p(<0.0001) \) than in the L group. Moreover, the H group had a higher prevalence of hypertension \( p(<0.0001) \), diabetes \( p=0.0011 \), respiratory disease \( p(<0.0001) \), cerebrovascular disease \( p(<0.0001) \), and cardiovascular disease \( p=0.0030 \) (Table 2). Multivariate logistic regression analysis revealed that female sex \( p=0.0054 \), advanced Steinbrocker class \( p(<0.0001) \), high ACPA levels \( p=0.0211 \), high PSL dose \( p(<0.0001) \), and absence of Bio/JAK use \( p(<0.0001) \) were risk factors for high disease activity; shorter treatment period was a low-risk factor for high disease activity \( p=0.0041 \). Among comorbidities, the presence of cerebrovascular disease \( p=0.0334 \) was associated with high disease activity (Table 3).

**Discussion**

Using our patient registry with a high proportion of elderly patients, we found that cerebrovascular disease was associated with high disease activity in patients with RA, among the comorbidities studied. Since patients from the registry had a higher average age of 66.4 years, and a higher prevalence of cardiovascular disease (8.0%) and cerebrovascular disease (4.7%) than those in other reports [4, 8, 18], this finding has important implications for the treatment of rheumatoid arthritis in the elderly.

In the comparison between the two groups, the H group was older, had more comorbidities, used MTX and Bio less often, and used a higher dose of PSL. This result is consistent with that of a previous study [14] which suggested that the presence of comorbidities influenced the choice of treatment. In addition, it has been reported that female RA patients who have a longer disease duration and belong to a higher disease functional class as per the Steinbrocker criteria do not respond to treatment as well as those with a shorter disease duration [19]. The results of our multivariate logistic regression analysis support these previous findings, indicating that early and adequate therapeutic intervention is necessary in the treatment of RA.

Conversely, it has been reported that RA is an independent risk factor for cardiovascular and cerebrovascular disease due to the progression of arteriosclerosis caused by chronic inflammation and decreased physical activity [20–24]. Previously, Crepaldi et al. reported that ischemic heart disease was related to RA disease...
activity [10]. However, in our study, cardiovascular disease, including ischemic heart disease, was not a risk factor for high disease activity. This may have been due to several reasons. First, Asians have a lower risk of developing ischemic heart disease than Westerners [25], and therefore, there may have been fewer patients with ischemic heart disease in our study. Second, in our registry, the category of “cardiovascular disease” included not only ischemic heart disease, but also heart failure and cardiomyopathy. Heart failure and cardiomyopathy do not directly correlate with RA disease activity, and this may have influenced our results.

The association between cerebrovascular disease and disease activity of RA has been previously reported, and proper treatment and maintenance of low disease activity in RA can suppress the progression of atherosclerosis [26], thereby reducing the risk of cerebrovascular events [27]. Our results suggest that cerebrovascular events may be more frequent in RA patients with high disease activity, and provide evidence for the effectiveness of appropriate treatment, including Bio, based on recent T2T strategies. Another possible interpretation is that patients with a history of cerebrovascular disease are not being treated appropriately. In fact, the physical limitations of patients have been reported to be barriers to achieving optimal disease activity [18], and the usage rate of biologics has been reported to be lower in patients with cerebrovascular disease because this comorbidity is attributed to increased fragility [28]. In this study as well, a high Steinbrocker class was a risk factor for high disease activity in the multivariate logistic regression analysis; impaired physical function was associated with high disease activity. Although the definition of patient fragility is unclear and the association between cerebrovascular disease and the patient’s physical function and usage rate of biologics has not been investigated in this study, we hypothesized that the general health condition of patients with a history of stroke influenced the treatment choice of their physicians and resulted in high disease activity.

| Variables                      | L group | H group | p value   |
|--------------------------------|---------|---------|-----------|
| Total patients                 | 1133    | 705     | <0.0001*  |
| Age (years)                    | 64.2±13.0 | 70.0±12.2 | 0.0055*  |
| Sex—male/female                | 251 (22.2)/882 (77.8) | 114 (16.2)/591 (83.8) | 0.0017*  |
| Disease duration (months)      | 145±120 | 162±141 | <0.0001*  |
| Steinbrocker stage I/II/III/IV  | 33.8/21.9/21.9/22.4 | 18.8/22.7/27.5/31.0 | <0.0001*  |
| Steinbrocker class I/II/III/IV  | 59.5/33.5/5.7/1.3 | 25.8/49.5/20.3/4.4 | <0.0001*  |
| ACPA (U/ml)                    | 114±173 | 181±436 | 0.0034*   |
| DAS                            | 2.2±0.7 | 4.1±0.8 | <0.0001*  |
| SDI                            | 3.9±3.2 | 12.7±7.5 | <0.0001*  |
| HAQ                            | 0.5±1.1 | 1.4±3.6 | <0.0001*  |
| DMARDs usage                   | 1133 (61.6) | 705 (38.4) | 0.0017*  |
| MTX usage                      | 711 (62.7) | 406 (57.6) | 0.0387*  |
| MTX dose (mg/week)             | 7.3±2.3 | 7.2±2.4 | 0.5686    |
| PSL usage                      | 370 (32.7) | 341 (48.4) | <0.0001*  |
| PSL dose (mg/day)              | 3.5±2.1 | 4.1±2.1 | <0.0001*  |
| Biologics/JAK usage            | 346 (30.5) | 155 (22.0) | <0.0001*  |

Values are expressed as the number of patients (%) or the mean ± SD

ACPA anticyclic citrullinated peptide antibody, DAS Disease Activity Score-28 joint count, HAQ Health Assessment Questionnaire, DMARDs disease-modifying anti-inflammatory drugs, MTX methotrexate, PSL prednisolone, JAK Janus kinase inhibitors, SD standard deviation

*Statistically significant
The presence of respiratory disease is the most important comorbidity to consider when treating patients with both MTX and biologics, as it increases the risk of drug-related risks, such as the development and exacerbation of IP and respiratory infections [28–30]. Therefore, respiratory disease could also be a risk factor for high disease activity in terms of drug selection. However, in this study, there was no statistically significant association between disease activity and respiratory disease in patients with RA. A previous study reported that respiratory comorbidity affected patient-reported outcomes [10]. However, to our knowledge, there are no studies that have revealed an association between RA disease activity and the presence of respiratory comorbidities. A variety of treatment options, including the careful use of MTX and biologics with close monitoring of symptoms [28, 31] and the use of some biologic agents with a low risk of infection but good efficacy in improving activity, could contribute to achieving low disease activity in patients with comorbid conditions [32, 33].

This study had several limitations. First, this was a cross-sectional observational study; hence, it was difficult to evaluate the influence of comorbidities on therapeutic response and selection of drugs, and to clearly establish a causal relationship between comorbidities, disease characteristics, and treatment. Second, we did not investigate other painful diseases, such as osteoarthritis and spondylitis, which may influence the assessment of disease activity. Although comorbidities generally increase in the elderly, we did not compare comorbidities in the non-RA group. Finally, our study was not limited to the elderly, as it included all RA patients older than 18 years. Finally, although our data is from the region with the highest rate of aging, our study is not limited to the elderly because we analyzed all registered cases, including all patients with RA aged 18 years and older. Further research is needed to confirm these findings by refining the registration methods, collecting more detailed data, and conducting longitudinal studies.

Conclusions
In our registry study with a high proportion of elderly RA patients, we revealed that in patients with moderate-to-high disease activity as classified by DAS28-ESR, the prevalence of hypertension, diabetes mellitus, respiratory disease, and cardio-cerebrovascular disease, but not renal disease and malignant tumor, was significantly higher. Furthermore, multivariate logistic regression analysis showed that among the comorbidities, only cerebrovascular disease was associated with high disease activity in patients with RA. Therefore, when treating elderly patients with RA, we need to pay careful attention to cerebrovascular disease, and treatment should be aimed at achieving adequate control of RA.

Abbreviations
RA: Rheumatoid arthritis; AORA: Akita Orthopedic Group on Rheumatoid Arthritis; DAS28-ESR: Disease activity score in 28 joints based on the erythrocyte sedimentation rate; DMARDs: Disease-modifying antirheumatic drugs; MTX: Methotrexate; Bio: Biologics; JAK: Janus kinase inhibitors; T2T: Treat-to-target; ACPA: Anti-citrullinated protein antibody; SDAI: Simplified disease activity index; HAQ: The health assessment questionnaire disability index; PSL: Prednisolone; DM: Diabetes mellitus; COPD: Chronic obstructive pulmonary disease; IP: Interstitial pneumonia; eGFR: Estimated glomerular filtration rate; SD: Standard deviation.

Acknowledgements
The authors would like to thank Moto Kobayashi, Masakazu Utayama, Natsuo Konishi, Hiroki Ito, Takayuki Tani, Tsutomu Sakuraba, Toshiaki Aizawa, Hidekazu Abe, Norio Suzuki, Keiji Kamo, Hiroshi Aonuma, Tetuya Kawano, and Yosuke Iwamoto for data collection and sharing their dataset with us.

Authors’ contributions
TM, NM, HT, and YS conceived and design the study, in addition to drafting the manuscript. TK data collected. YS gave final approval. All authors read and approved the final manuscript.

Funding
The authors received no specific funding for this work.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

| Variables                  | OR   | 95%CI            | p value |
|---------------------------|------|------------------|---------|
| Age                       | 1.0005 | 0.9923–1.0183 | 0.4303  |
| Female                    | 1.7759 | 1.9151–2.6826 | 0.0054* |
| Disease duration          | 0.9979 | 0.9965–0.9993 | 0.0041* |
| Steinbrocker stage        | 1.1723 | 0.9972–1.3786 | 0.0540  |
| Steinbrocker class        | 2.4559 | 1.9617–3.0942 | <0.0001* |
| ACPA                      | 1.0008 | 1.0001–1.0016 | 0.0211* |
| MTX usage                 | 1.0330 | 0.7607–1.4072 | 0.8356  |
| PSL usage                 | 1.8142 | 1.3524–2.4352 | <0.0001* |
| Biologics/JAK usage       | 0.4870 | 0.3431–0.6849 | <0.0001* |
| Hypertension              | 1.0769 | 0.7698–1.5013 | 0.6632  |
| Diabetes mellitus         | 1.2927 | 0.7782–2.1835 | 0.3182  |
| Respiratory disease       | 1.4247 | 0.9261–2.1846 | 0.1053  |
| Cerebrovascular disease   | 1.8682 | 1.0642–3.6347 | 0.0334* |
| Cardiovascular disease    | 1.5137 | 0.8912–2.5645 | 0.1229  |
| Renal disease             | 1.1947 | 0.8229–1.7320 | 0.3479  |
| Malignant tumor           | 0.7047 | 0.3762–1.2753 | 0.2590  |

OR: odds ratio, CI: confidence interval, ACPA: anticyclic citrullinated peptide antibody, MTX: methotrexate, PSL: prednisolone, JAK: Janus kinase inhibitors

*Statistically significant
References

1. Shoult CA, Crowson CS, Gabriel SE, Matteson EL (2012) Orthopedic surgery among patients with rheumatoid arthritis 1980-2007: a population-based study focused on surgical rates, sex, and mortality. J Rheumatol 39:481–485. https://doi.org/10.3899/jrheum.1101506

2. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas DT, Burmester GR et al (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69:631–637. https://doi.org/10.1136/ard.2009.123919

3. Rasch EK, Hirsh R, Paulose-Ram R, Hochberg MC (2003) Prevalence of rheumatoid arthritis in persons over 60 years of age and older in the United States: Effect of different methods of case classification. Arthritis & Rheumatism 48:917–916. https://doi.org/10.1002/art.10897

4. Köller MD, Aletaha D, Funovits J, Pangan A, Baker D, Smolen JS (2009) Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients. Rheumatology 48:1575–1580. https://doi.org/10.1093/rheumatology/kep291

5. Burmester GR, Ferraccioli G, Elipo R-M, Monteagudo-Sáez I, Unnebrink K, Kary S et al (2008) Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. Arthritis Rheum 59:32–41. https://doi.org/10.1002/art.23247

6. Sokka T, Mäkinen H, Hannonen P, Pincus T (2007) Most people over age 50 in the general population do not meet ACR remission criteria or OMERACT minimal disease activity criteria for rheumatoid arthritis. Rheumatology 46:1020–1023. https://doi.org/10.1093/rheumatology/kem051

7. Trehame GJ, Douglas KM, Ivasko J, Panoulas VF, Hale ED, Minton DL et al (2007) Polypharmacy among people with rheumatoid arthritis: the role of age, disease duration and comorbidity. Musculoskeletal Care 5:175–190. https://doi.org/10.1016/j.msc.2007.06.002

8. Jung SM, Kwok SK, Ju H, Lee SW, Song JI, Yoon CH et al (2018) Risk factors associated with inadequate control of disease activity in elderly patients with rheumatoid arthritis: results from a nationwide KORean Collage of Rheumatology BIolOgics (KOBIO) registry. PLoS ONE 13:e0205651. https://doi.org/10.1371/journal.pone.0205651

9. Ranganath VK, Maranian P, Elashoff DA, Woodworth T, Khanna D, Hahn T et al (2013) Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis. Rheumatology (Oxford) 52:1809–1817. https://doi.org/10.1093/rheumatology/ket224

10. Cipolletti G, Scire CA, Carraa G, Sakellariou G, Caporali R, Hmamouchi I et al (2016) Cardiovascular comorbidities relate more than others with disease activity in rheumatoid arthritis. PLoS ONE 11:e0146991. https://doi.org/10.1371/journal.pone.0146991

11. Sugimura Y, Miyakoshi N, Miyamoto S, Kasukawa Y, Hongo M, Shimada Y (2016) Prevalence of and factors associated with lumbar spondylosis in patients with rheumatoid arthritis. Mod Rheumatol 26:342–346. https://doi.org/10.1007/s10162-015-10813-26

12. Statistics Bureau Home Page/Population Census. 2020. http://www.stat.go.jp/english/data/kokuseki/index.html. Accessed 5 Apr 2020.

13. Dougados M, Soubrier M, Antunez A (2014) Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 73:62–68. https://doi.org/10.1136/annrheumdis-2014-204223

14. Nakajima A, Inoue E, Shimizu Y, Kobayashi A, Shidara K, Sugimoto N et al (2014) Presence of comorbidity affects both treatment strategies and outcomes in disease activity, physical function, and quality of life in patients with rheumatoid arthritis. Clin Rheumatol 34:441–449. https://doi.org/10.1007/s10067-014-2750-8

15. Steinbrocker O, Traeger CH, Bateman RC (1949) Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 140:659–662. https://doi.org/10.1001/jama.1949.02900430001001

16. Hallan S, Matsushita K, Sung Y, Mahmoodi BK, Black C, Ishani A et al (2012) Age and the association of kidney measures with mortality and end-stage renal disease. J Am Med Assoc 308:2349–2360. https://doi.org/10.1001/jama.2012.18617

17. van der Heijde DM, van't Hof M, van Riel PL, van de Putte LB (1993) Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 20:579–581.

18. Owensby JK, Chen L, O'Beirne R, Ruderman EM, Harrold LR, Melnick JA et al (2019) Patient and rheumatologist perspectives regarding challenges to achieving optimal disease control in rheumatoid arthritis. Arthritis Care Res (Hoboken) 72:993–941. https://doi.org/10.1002/acr.23907

19. Anderson JJ, Wells G, Verhoeven AC, Felson DT (2000) Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 43(1):22–29. https://doi.org/10.1002/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO;2-9

20. Arts EEA, Fransen J, den Broeder AA, Popa CD, van Riel PLCM (2015) The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients. Ann Rheum Dis 74:998–1003. https://doi.org/10.1136/annrheumdis-2013-204531

21. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandli LA, Manson JE et al (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107:1303–1307. https://doi.org/10.1161/01.CIR.0000046127.26458.82

22. Wiseman SJ, Ralston SH, Wardlaw JM (2016) Cerebrovascular disease in rheumatoid diseases a systematic review and meta-analysis. Stroke 47:943–950. https://doi.org/10.1161/STROKEAHA.115.012052

23. Michaud K, Wolfe F (2007) Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol 21:885–906. https://doi.org/10.1016/j.berh.2007.06.002

24. Peters MJL, Symmons DPM, McCoy D, Szekeczecz Z, Sattar N, McInnes IB et al (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69:325–331. https://doi.org/10.1136/annrheumdis-2010-200688

25. Hirotsugu U, Akira S, Katsuyuki M, Turin TC, Takashima N, Kita Y et al (2008) Cardiovascular disease and risk factors in Asia: a selected review. Circulation 118:270227–270209. https://doi.org/10.1161/CIRCULATIONAHA.110.956839

26. Airda A, Protogerou AD, Konstantinou G, Fragiadaki K, Kitas GD, Sifakis PP (2017) Atherosclerosis is not accelerated in rheumatoid arthritis of low activity or remission, regardless of antirheumatic treatment modalities. Rheumatology 56:934–939. https://doi.org/10.1093/rheumatology/kew506

27. Tang C-H, Yu F, Huang C-Y, Chen D-Y (2019) Potential benefits of biologicals on stroke and mortality in patients with rheumatoid arthritis: A nationwide population-based cohort study in Taiwan. Int J Rheum Dis 22:1544–1552. https://doi.org/10.1111/1756-185X.13611

28. Bengtsson K, Jacobsson LTH, Rydberg B, Kvist G, Torstenson T, Dehlin M et al (2016) Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: a register-based study. BMC Musculoskeletal Disord 17:1–10. https://doi.org/10.1186/s12891-016-1354
29. Tokuda H, Harigai M, Kameda H, Tomono K, Takayanagi N, Watanabe A et al (2017) Consensus statements for medical practice: Biological agents and Lung disease [Abridged English translation by the Japanese Respiratory Society]. Respir Investig 55:229–251. https://doi.org/10.1016/j.resinv.2017.01.002

30. Roubille C, Haraoui B (2014) Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum 43:613–626. https://doi.org/10.1016/j.semarthrit.2013.09.005

31. Alarcon GS, Kremer JM, Macaluso M, Weinblatt ME, Cannon GW, Palmer WR (1997) Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis: A multicenter, case-control study. Ann Intern Med 127:356–364. https://doi.org/10.7326/0003-4819-127-5-199709010-00003

32. Yun H, Xie F, Delzell E, Levitan EB, Chen L, Lewis JD et al (2016) Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in Medicare. Arthritis Rheumatol 68:56–66. https://doi.org/10.1002/art.39399

33. Ebina K, Hashimoto M, Yamamoto W, Hirano T, Hara R, Katayama M et al (2019) Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study. PLoS ONE 14:e0216624. https://doi.org/10.1371/journal.pone.0216624

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.